ARTICLE

FindCenter AddIcon

Ketamine for Depression Still Too Expensive for Widespread Use

By Technology Networks — 2020

A paper authored by researchers from McLean Hospital has determined that esketamine, a nasal spray to treat severe depression, is currently too expensive for widespread use. The study compared the costs and benefits of esketamine, an antidepressant approved by the U.S. Food and Drug Administration (FDA) last year for use in treatment-resistant major depressive disorder.

Read on www.technologynetworks.com

FindCenter Post-Image

Experimental Treatments Changed the Course of the AIDS Epidemic; We Need the Same Approach to Mental Illness Today | Commentary

Demand from patients seeking help for their mental illnesses has led to underground use in a way that parallels black markets in the AIDS pandemic. This underground use has been most perilous for people of color, who face greater stigma and legal risks due to the War on Drugs.

Article
Monnica Williams, Morgan Campbell
2021
FindCenter AddIcon
FindCenter Post-Image

An Introduction to MDMA

Once considered the quintessential party drug, MDMA (also known as “ecstasy,” “X,” or “molly”) is now experiencing a surge of interest in a completely different area: psychedelic-assisted psychotherapy.

Article
FindCenter
2022
FindCenter AddIcon
FindCenter Post-Image

Meet the Psychologist Using Psychedelics to Treat Racial Trauma

People of color are dealing with racism all the time, in large and small ways, and even dealing with racism in healthcare, even dealing with racism in therapy.

Article
Robin Donovan
2021
FindCenter AddIcon
FindCenter Post-Image

Psychedelic Therapy and Racial Trauma: Offering Clients a Deeper Experience of Healing

Like most people of color in the United States, psychotherapist and researcher Monnica Williams has experienced myriad forms of racism. Early in her career, understanding its effects on her mind and body motivated her to help clients address their own racial trauma in therapy.

Article
Chris Lyford
2021
FindCenter AddIcon
FindCenter Post-Image

The Cost of Exclusion in Psychedelic Research

In the last two decades, researchers have started to reexamine psychedelics for their therapeutic potential. Though initial results seem promising, the research has a significant shortcoming: the lack of racial and ethnic diversity among research teams and study participants.

Article
Xinyuan Chen, Mackenzie Bullard, Christy Duan, Jamilah R. George, Terence Ching, Stephanie Kilpatrick, Jordan Sloshower, Monnica Williams
2020
FindCenter AddIcon
FindCenter Post-Image

Psychedelic Psychotherapy Is Coming: Who Will Be Included?

A new study finds widespread exclusion of minorities in psychedelic research.

Article
Monnica T. Williams
2018
FindCenter AddIcon
FindCenter Post-Image

How Researchers and Advocates of Color Are Forging Their Own Paths in Psychedelic-Assisted Therapy

We’re seeing an explosion of medical research into psychedelics. Psilocybin, or shrooms, to treat major depressive disorder. Ayahuasca, a psychotropic plant medicine from the Amazon, and ibogaine, a potent hallucinogen from Africa, to treat addiction. LSD for anxiety.

Article
Steph Yin
2020
FindCenter AddIcon
FindCenter Post-Image

Who Will Benefit From Psychedelic Medicine?

These substances are being touted as a game-changing intervention for mental health. But it’s not clear if their promise will be accessible to all.

Article
Whitney Joiner
2020
FindCenter AddIcon
FindCenter Post-Image

Psychedelics Shown to Ease the Effects of Racial Trauma

A recent study found that even a single positive psychedelic experience may ease mental health symptoms associated with racial trauma experienced by Black, Indigenous, and people of color (BIPOC).

Article
Kristi Pahr
2021
FindCenter AddIcon
FindCenter Post-Image

5 Women in Psychedelics You Should Know About

Badass women making waves in the psychedelic movement, from research to drug policy reform.

Article
Michelle Janikian
2019
FindCenter AddIcon

EXPLORE TOPIC

Clinical Depression